Table 1.
Demographic characteristics of the vaccinated study population.
| Patients Characteristics | All-Vac Group (n = 437) | No Vac-Group (n = 375) |
|---|---|---|
| Mean age ± SD, years (range) | 64 ± 14 (21–88) | 61 ± 14.5 (16–87) |
| Female, n (%) | 205 (47%) | 178 (48%) |
| PET/CT indication, n (%) | ||
| Hematological malignancy | 107 (25%) | 93 (25%) |
| Breast malignancy | 53 (12%) | 47 (13%) |
| Lung malignancy | 76 (17%) | 53 (14%) |
| Gastrointestinal malignancy | 56 (13%) | 45 (12%) |
| Gynecological malignancy | 21 (5%) | 15 (4%) |
| Genitourinary malignancy | 61 (14%) | 50 (13%) |
| Head and neck malignancy | 23 (5%) | 26 (7%) |
| Sarcoma | 5 (1%) | 4 (1%) |
| Melanoma | 17 (4%) | 17 (5%) |
| Inflammation/infection | 10 (2%) | 12 (3%) |
| Other malignancy | 8 (2%) | 13 (3%) |
| Extension of disease, n (%) | ||
| Localized disease | 162 (37%) | 157 (42%) |
| Metastatic disease | 275 (63%) | 218 (58%) |
| Status of Disease, n (%) | ||
| Diagnosis/staging | 129 (30%) | 96 (26%) |
| Interim/post-therapy | 159 (36%) | 146 (39%) |
| Follow-up | 149 (34%) | 133 (35%) |
| Treatment, n (%) | ||
| No current treatment | 306 (70%) | 283 (75%) |
| Chemotherapy | 55 (13%) | 35 (9%) |
| Immunosuppressive/ Immunotherapy |
27 (6%) | 21 (6%) |
| Other | 49 (11%) | 36 (10%) |
| Vaccination data, n (%) | ||
| Vac-1 group | 153 (35%) | |
| Vac-2 group | 284 (65%) | |
| Type of vaccination, n (%) | ||
| BioNTech/Pfizer | 380 (87%) | |
| Moderna | 26 (6%) | |
| AstraZeneca | 31 (7%) | |
| Median time vaccination-PET/CT, days | 23 |